Longbio Pharma
13
1
5
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 13 trials
100.0%
+13.5% vs industry average
8%
1 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
A Study of Single Dose of LP-003 in Adolescent Subjects
Role: lead
A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Role: lead
Efficacy and Safety of LP-005 Injection in Patients With Complement-Mediated Kidney Disease
Role: lead
Efficacy, Safety, and Pharmacokinetics of LP-005 Injection in PNH Patients.
Role: lead
Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma Patients
Role: lead
Efficacy and Safety of LP-003 Injection in Patients With Moderate to Severe Seasonal Allergic Rhinitis
Role: lead
A Study of Single Dose of LP-003 in Healthy Adult Subjects
Role: lead
A Study of Single and Multiple Doses of LP-005 in Healthy Adult Participants
Role: lead
A Study of Single and Multiple Dose Administration of LP-001 in Healthy Subjects
Role: lead
Efficacy and Safety of LP-003 in Moderate-to-severe Seasonal Allergic Rhinitis Adult
Role: lead
A Study of Single and Multiple Doses of LP-003 in Healthy Adult Participants
Role: lead
Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment
Role: lead
Efficacy, Safety, and Pharmacokinetics of LP-005 Injection in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Role: lead
All 13 trials loaded